Using a specialized lab technique, scientists identified early cellular changes that may help drive lung scarring in ...

Tyvaso significantly improved a measure of lung function for IPF patients in a Phase 3 trial, which top-line data showed met ...

Columnist Sam Kirton talks to Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation, about the need for better research.

Pulmonary fibrosis (PF) is characterized by scarring, or fibrosis, in the lungs. Scar tissue development can interfere with the lungs’ ability to deliver oxygen to the bloodstream, as well as with ...

According to the National Institutes of Health (NIH), about 100,000 people in the U.S. have pulmonary fibrosis. Between 30,000 and 40,000 new cases are diagnosed every year. While inherited pulmonary ...

Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial of LTI-03, a therapy candidate for idiopathic pulmonary fibrosis (IPF), after receiving ...